A555were elicited from an expert panel of 6 hematologists with the Delphi technique. Unit costs were taken from officially published Greek sources (Ministry of Health, Social Insurance Funds). Utility data were taken from a published UK study. Only direct costs were considered in the analysis and the cost base year was 2016. The time horizon was lifetime and the perspective adopted was the societal. Future costs and outcomes were discounted at 3.5%. Probabilistic sensitivity analysis (PSA) was performed to test robustness of model results. Results: GClb was associated with higher mean costs (€ 24,874) but also with higher life years gained (LYs -5.70) and quality adjusted life years (QALYs) 3.95 versus all comparators. The incremental cost effectiveness ratio (ICER) of GClb versus RClb was estimated at € 15,679 per LY and € 16,614 per QALY gained. The respective ICERs versus Clb, OClb and RBenda were estimated at
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.